A leading biopharma company
-
People worldwide
70k -
Countries we operate in
80+ -
Manufacturing sites
37 -
Countries that receive GSK products
112
Innovation
-
R&D investment in 2022
£5.5bn -
People working in R&D
15k -
R&D centres
4 -
New collaborations and acquisitions in 2022
7
Performance
-
Vaccine doses and medicine packs delivered in 2022
2.3bn -
Vaccine and medicine sales in 2022
£29.3bn -
Products exceeding £1bn sales
10
Trust
-
In the Access to Medicine Index
1st -
In our industry for the S&P Global Corporate Sustainability Assessment
2nd
Products and pipeline
-
Vaccines and medicines that are currently in development
68 -
Number of phase I programmes started in 2022
16 -
Number of assets in phase III/registration in 2022
18 -
Major new vaccines and medicines approved since mid 2017
>20
-
Vaccines in our portfolio
20+ -
Vaccine doses delivered each day
1.5m -
Children receiving a GSK vaccine each year
4 in 10
-
To pioneer HIV treatments in 1980 and leaders in HIV innovation
1st -
New medicine for Lupus in 50+ years
1st
-
Patients reached with our general medicines over the next ten years
700m -
Medicines in our portfolio
150+ -
Helping millions of people with respiratory conditions to breathe more easily
50 years
